COEP - NASDAQ
Coeptis Therapeutics, Inc.
$16.40
+0.0000%Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
At a Glance
Live Snapshotcoep
Additional Paid-In Capital
Last Annual Value
127.20M
3-Year CAGR
22%
5-Year CAGR
70%
10-Year CAGR
%
Coeptis Therapeutics, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Coeptis Therapeutics, Inc. NASDAQ:COEP | 127.20M | 11.5% | 33.4% | N/A | |
 Century Therapeutics, Inc. NASDAQ:IPSC | 950.81M | 4.2% | 3.9% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 290.93M | 6.4% | 7.4% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 0.00 | N/A | N/A | N/A | |
 Equillium, Inc. NASDAQ:EQ | 244.43M | 5.5% | 6.7% | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 394.80M | 5.3% | 8.5% | 31.9% | |
 Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | 387.25M | 17.7% | 225.9% | N/A | |
 Fortress Biotech, Inc. NASDAQ:FBIO | 783.89M | 3.0% | 3.6% | 10.7% | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 886.02M | 0.9% | 9.1% | 73.7% | |
 Karyopharm Therapeutics Inc. NASDAQ:KPTI | 1.47B | 2.8% | 5.9% | 10.7% | |
 OS Therapies Incorporated NYSE:OSTX | 35.14M | 85.6% | 56.4% | N/A |
Coeptis Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your COEP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.